New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
07:32 EDTREGNRegeneron, Bayer announce positive Phase 3 Eylea trial results
Regeneron and Bayer HealthCare announced that in the Phase 3 VISTA-DME trial of EYLEA Injection for the treatment of diabetic macular edema, EYLEA 2 milligrams dosed monthly and EYLEA 2 mg dosed every two months showed a sustained improvement from baseline in best corrected visual acuity at week 100, compared to laser photocoagulation. After two years, patients receiving EYLEA 2Q4 had a mean change from baseline in BCVA of 11.5 letters. Patients receiving EYLEA 2Q8 had a mean change from baseline in BCVA of 11.1 letters. Patients in the laser photocoagulation treatment group had a mean change from baseline in BCVA of 0.9 letters. In this trial, EYLEA was generally well tolerated with a similar overall incidence of adverse events, ocular serious AEs, and non-ocular serious AEs across the EYLEA treatment groups and the laser control group. Bayer HealthCare and Regeneron are collaborating on the global development of EYLEA.
News For REGN From The Last 14 Days
Check below for free stories on REGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 8, 2014
07:15 EDTREGNIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
September 4, 2014
05:37 EDTREGNRegeneron submits application for Eylea injection in Japan for macular edema
Subscribe for More Information
September 2, 2014
13:58 EDTREGNRegeneron expected to receive priority review at Piper Jaffray
Piper Jaffray expects Regeneron (REGN) and Sanofi (SNY) will receive priority review for alirocumab via the priority review voucher recently acquired from BioMarin (BMRN). Piper says potential approval of the drug is likely by mid-2015 and it reiterates an Overweight rating on Regeneron with a $382 price target.
13:48 EDTREGNRegeneron price target raised to $390 from $380 at Brean Capital
Subscribe for More Information
08:04 EDTREGNRegeneron price target raised to $436 from $389 at Leerink
Leerink raised its price target for Regeneron shares to $436 after its survey of 100 physicians indicated potential blockbuster status for the company's PCSK9-inhibitor Alirocumab. The firm reiterates an Outperform rating on the stock.
07:21 EDTREGNRegeneron data positive, says RBC Capital
Subscribe for More Information
07:14 EDTREGNRegeneron price target raised to $400 from $340 at Credit Suisse
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use